- CFO Spotlights
- Profiles
- Yanina Grant-Huerta
Profile
Yanina Grant-Huerta
Chief Financial Officer, principal financial officer and principal accounting officer, ImageneBio, Inc.
In the seat. First published here October 28, 2026; built from records as of October 28, 2026.
Yanina Grant-Huerta has been Chief Financial Officer, principal financial officer and principal accounting officer of ImageneBio, Inc. since July 20, 2026, according to the company's filing of July 23, 2026.2
The filing gives Yanina Grant-Huerta's previous role as Chief Accounting Officer at Atara Biotherapeutics, Inc.2 Yanina Grant-Huerta joined from outside ImageneBio, Inc., by the record's reading of the filing.2
The record also places Yanina Grant-Huerta in the finance seat at one other company: Atara Biotherapeutics, Inc. (a later filing names a successor). Each is set out below, filing by filing.
Seats
2 seats in the record
| Company | Title as filed | Standing |
|---|---|---|
| ImageneBio, Inc. (IMA) Biological Products, (No Diagnostic Substances) | Chief Financial Officer, principal financial officer and principal accounting officer | In the seat |
| Atara Biotherapeutics, Inc. (ATRA) Biological Products, (No Diagnostic Substances) | Chief Accounting Officer ( Principal Financial and Accounting Officer ) | A later filing names a successor Kevin G. Sarney, filed June 26, 2026 (filing) |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- July 20, 2026effective
ImageneBio, Inc. appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer and principal accounting officer, effective July 20, 2026. Profile of Kristin Yarema, Ph.D..
On July 20, 2026, ImageneBio, Inc., a Delaware corporation (the “Company”), based in part on the recommendation of Kristin Yarema, Ph.D., the Company’s Chief Executive Officer, appointed Yanina Grant-Huerta as the Company’s Chief Financial Officer, principal financial officer […]
[2] Filing by ImageneBio, Inc., filed with the SEC on July 23, 2026. Read the filing. The record at CFO Tribune.
- March 16, 202610-K filed
Yanina Grant-Huerta signed the annual report of Atara Biotherapeutics, Inc. on Form 10-K as Chief Accounting Officer ( Principal Financial and Accounting Officer ), filed March 16, 2026.
/s/ Yanina Grant-Huerta Yanina Grant-Huerta Chief Accounting Officer ( Principal Financial and Accounting Officer )
[1] Annual report on Form 10-K by Atara Biotherapeutics, Inc., filed with the SEC on March 16, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Annual report on Form 10-K, Atara Biotherapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 16, 2026. sec.gov; record.
- Current report filed with the SEC, ImageneBio, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 23, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Yanina Grant-Huerta wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.